harmacological manipulation is an important tool for understanding the regulation of transcription 1 . For example, the identification of DRB (5,6-dichloro-1-β-D-ribofuranosylbenzimidazole) as a transcription elongation inhibitor 2 facilitated the identification of the protein factors pTEFb, DSIF, and NELF that regulate transcription elongation [3] [4] [5] . The importance of these factors in regulating elongation was subsequently reinforced by the discovery that DRB shares a common target with a second elongation inhibitor, flavopiridol (FP) 6, 7 . Both DRB and FP inhibit the kinase activity of the pTEFb subunit CDK9, blocking phosphorylation of serine 2 in the RNA polymerase C-terminal domain (CTD) [8] [9] [10] [11] . Regulation of transcription elongation via pTEFb is now recognized as an important mode of gene regulation 12, 13 , although pTEFb is not the only CTD kinase 14, 15 . The usefulness of DRB and FP in understanding transcription elongation suggests that the identification of additional compounds that regulate specific stages of mRNA synthesis will reveal new regulatory mechanisms.
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Current approaches for screening small molecules that affect mRNA synthesis have substantial limitations. In both screens and subsequent characterization, specific steps of mRNA synthesis (e.g., transcription initiation, elongation, and splicing) are typically tested separately despite their interdependence 16 . Consequently, the predominant regulatory effects of a small molecule may be missed. One potential example is the biflavonoid isoginkgetin (IsoG), first isolated from the extract of Ginkgo biloba leaves. IsoG is one of the few reported chemical inhibitors of splicing and the first that does not target the SF3b subunit of the U2 small nuclear ribonucleoprotein particle (snRNP) 17, 18 . Splicing inhibition of IsoG was first reported in an in vivo screen in which splicing inhibition was linked to an increase in the activity of a luciferase reporter gene 19 . IsoG causes an accumulation of unspliced endogenous pre-mRNAs [19] [20] [21] as well as an enlargement of splicing factor compartments 22 . In vitro, IsoG blocks splicing and stalls spliceosome assembly in the A complex before assembly of a catalytically active spliceosome 19 . In addition to its reported inhibition of splicing, IsoG was also recently reported to cause accumulation of transcription start site (TSS)-proximal antisense RNAs (PROMPTs) at the human telomerase RNA gene, suggesting that IsoG may inhibit nuclear RNA exosome-mediated degradation 21 . Unfortunately, both in vivo splicing and in vivo exosome functions are typically assessed under the implicit assumption that transcription is unaffected. However, it is reasonable to suspect that compounds such as IsoG that influence splicing may also influence transcription; splicing factors are required for transcription elongation [23] [24] [25] [26] [27] , and transcription influences splicing as well 16, 28 . The specific targets of IsoG are not known, and it remains possible that the primary effect of IsoG is on transcription rather than splicing or exosome function.
We previously demonstrated that strand-specific total RNA sequencing (RNA-seq), with appropriate analysis, can be used to separately probe transcription initiation, elongation, and splicing 20, 29 .
Here we demonstrate the power of strand-specific total RNA-seq for screening and classifying small molecules that regulate mRNA synthesis. Surprisingly, we found that IsoG inhibits promoterproximal transcription elongation. The effects of IsoG treatment on elongation superficially resemble those of CDK9 inhibitors. Both reduce pre-mRNA expression levels and decrease phosphoserine 2 in the RNA polymerase II CTD. However, IsoG does not inhibit CDK9, and it causes RNA polymerase to accumulate within a broader promoter-proximal band than is seen with CDK9 inhibitors. Our data reveal at least three major locations at which smallmolecule-mediated transcription-elongation inhibition occurs: at the promoter (CDK9 inhibition), near the promoter (IsoG), and across the remainder of gene bodies (topoisomerase I inhibition). Strand-specific total RNA-seq can distinguish these effects on transcription elongation from deficits in exosomal processing, splicing, and transcription termination. Our results highlight the power of total RNA-seq as a tool for screening and target identification.
RESULTS

Total RNA-seq reveals that IsoG inhibits elongation
To identify specific stages of mRNA synthesis influenced by IsoG, we performed strand-specific total RNA-seq on IsoG-treated HeLa cells article NATURE CHEmICAL bIoLoGy dOI: 10.1038/nCHeMBIO.2317 (see Supplementary Table 1 for a summary of all RNA-seq data). We had previously performed a similar experiment in which we confirmed a modest splicing defect in IsoG-treated cells 20 . Here we sought to develop simple total RNA-seq analysis metrics that would allow us to comprehensively assess any effects on mRNA synthesis. We first asked whether IsoG causes alterations in the abundances of promoter-proximal RNA transcripts, since changes in their levels can reflect defects in multiple gene-expression processes. We examined the abundance of promoter-proximal RNA transcripts using TSS metaplots that bioinformatically exclude mature mRNA transcripts by omitting sequencing reads that align to annotated exons. We reasoned that the exclusion of mature mRNA would improve sensitivity for detecting defects in transcription and pre-mRNA processing, similar to performing RNA-seq on chromatin-associated RNAs 30 . Upon IsoG treatment we observed a global increase in the abundance of promoter-proximal RNA transcripts, including increases in the abundance of both sense and antisense transcripts (Fig. 1a) . In addition to increasing promoter-proximal transcripts, IsoG also decreases promoter-distal pre-mRNA transcripts, beginning ~5 kb downstream of the TSS. The promoter-proximal transcripts induced by IsoG are largely eliminated by poly(A) purification (Fig. 1b) , highlighting the advantage of performing total RNA-seq when characterizing the gene regulatory effects of small molecules (Fig. 1) .
We reasoned that strand-specific total RNA-seq should be able to distinguish between two classes of explanations for the increase in promoter-proximal RNA transcripts in IsoG-treated cells: a defect in the exosomal degradation of promoter-proximal transcripts and a defect in transcription elongation. We first asked whether the increase in promoter-proximal transcripts upon IsoG treatment could, as previously suggested 21 , be due to inhibition of the nuclear exosome, a complex that degrades promoter-proximal RNAs 31 . In an analysis of published total RNA-seq data, we found that IsoG and knockdown of exosome subunits RRP40 and RRP6 all lead to a global increase of sense and antisense promoter-proximal RNAs relative to mature mRNAs ( Fig. 2a; Supplementary Results,  Supplementary Fig. 1a) . However, the effects of exosome knockdown and IsoG treatment are distinct: compared to IsoG treatment, exosome knockdown leads to a greater increase in antisense compared to sense promoter-proximal transcripts (Fig. 2a) , consistent with the exosome having a specific function in the degradation of antisense transcripts 31 . This distinction is captured by an 'antisense TSS/sense TSS metric' based on the ratio of promoter-proximal antisense to sense RNA-seq signal, which is significantly elevated upon exosome knockdown but not IsoG treatment ( Fig. 2b; see Supplementary Fig. 2a-e and Online Methods for schematization and detailed description of this and subsequent metrics). Additionally, unlike IsoG treatment, exosome knockdown does not decrease promoter-distal pre-mRNA transcript abundance (Supplementary Fig. 1a) . These results suggest that the increase in promoter-proximal RNAs in IsoG-treated cells is not due to a defect in exosomal degradation.
We used strand-specific total RNA-seq to investigate the alternative hypothesis that IsoG inhibits transcription elongation by comparing IsoG to the well-characterized transcription elongation inhibitors DRB and FP in side-by-side total RNA-seq experiments. We found that all three compounds decrease promoter-distal premRNA transcript abundance (compared to External RNA Control Consortium (ERCC) spike-ins; Supplementary Fig. 2f ). In addition, all three compounds increase the ratio of promoter-proximal to promoter-distal transcript abundance, quantified in a 'TSS/genebody metric' (P < 0.05; Bonferroni-adjusted one-tailed t-test; Fig. 2c,d) . However, only IsoG causes a large increase in promoter-proximal transcript abundance (Supplementary Fig. 1b) . Our inability to detect increases in promoter-proximal transcripts that were previously observed with global run-on sequencing (GRO-seq) upon FP treatment 32 may be due to the fact that short (<60 bp) transcripts are not detectable by our total RNA-seq method. Another distinction between IsoG and DRB (or FP) is that RNA-seq read density remains elevated at greater distances from the TSS upon IsoG than upon DRB or FP treatment ( Fig. 2c; Supplementary  Fig. 1b) . The similarity between the FP, DRB, and IsoG profiles is consistent with the idea that IsoG causes slowing, stalling, or termination of RNA polymerase near promoters, although further from the TSS than that caused by CDK9 inhibition.
Splicing inhibition does not generally block elongation
We investigated whether the apparent defect in transcription elongation in IsoG-treated cells is a general consequence of IsoG's inhibition of splicing. This hypothesis was appealing because transcription and splicing are mechanistically coupled 16, [23] [24] [25] . We therefore performed strand-specific total RNA-seq on cells treated with the splicing factor 3b (SF3b) complex inhibitor meayamycin (MY), which inhibits U2 binding to the branchpoint of pre-mRNA (Fig. 2e) 33, 34 . We found that, unlike IsoG, meayamycin does not affect promoterproximal transcript abundance or increase the TSS/gene-body metric ( Fig. 2d; Supplementary Fig. 1c) . Nor does spliceostatin A (SSA), a related splicing inhibitor derived from the same natural product ( Fig. 2d; Supplementary Fig. 1d ). However, as expected, these inhibitors do inhibit splicing. Meayamycin treatment leads to accumulation of unspliced IkB pre-mRNA ( Supplementary Fig. 3a) , and both meayamycin and SSA increase an 'intron/exon metric' , defined as the ratio of intronic to exonic RNA-seq read densities (Fig. 2f) . This metric is ill-suited for assessing splicing defects of compounds that also affect transcription elongation, as these compounds will tend to reduce pre-mRNA more than mature mRNA levels (e.g., DRB, FP, and IsoG; Fig. 2f ). However, for compounds that do not affect elongation, the intron/exon metric is a useful proxy for splicing because of its simplicity as well as the minimal read depth that it requires compared to more accurate total-RNAseq-based metrics 20 . The observation that meayamycin and SSA inhibit splicing without inhibiting promoter-proximal elongation indicates that inhibition of splicing per se does not interfere with transcription elongation; hence, the effect of IsoG on transcription elongation is not a simple consequence of its inhibition of splicing. Our total RNA-seq analysis suggests that IsoG treatment also causes an apparent increase in transcriptional read through, wherein RNA polymerase transcription fails to terminate downstream of annotated cleavage and polyadenylation sites (PASs) ( Fig. 2a;  Supplementary Fig. 1e ). This apparent defect in transcription termination can be captured by a 'PAS-downstream/PAS metric' , based on the decrease in RNA-seq signal over the 10 kb downstream of the PAS (Fig. 2g) . Based on this metric, we observe no defect in termination upon treatment with DRB or FP (P < 0.05; Bonferroni-adjusted one tailed t-test), suggesting that the termination defect observed upon IsoG treatment is not a general consequence of interfering with promoter-proximal transcription elongation. Exosome knockdown increases the abundance of PAS-proximal transcripts, consistent with its function in RNA degradation (Supplementary Fig. 1a) . However, unlike IsoG, it does not increase the PAS-downstream/PAS metric (Fig. 2g) . By contrast, SSA and meayamycin treatment do cause an apparent defect in transcription termination ( Fig. 2e,g;  Supplementary Fig. 1d ), similarly to IsoG treatment. It is possible that IsoG, SSA, and meayamycin influence termination indirectly via their inhibition of splicing, since splicing facilitates recruitment of cleavage and polyadenylation machinery 35 . These results suggest that pharmacological effects on exosomal degradation and transcription termination can be distinguished via their distinctive PAS-proximal total RNA-seq signatures.
metagene metrics classify inhibitors by affected process
Having developed a set of metagene-based metrics that enable quantification of small-molecule effects on individual stages of mRNA synthesis, we also assessed the ability of these metrics to classify compounds based on their specific effects on gene expression, via unbiased clustering. Clustering based on our metrics 'correctly' classifies three transcription elongation inhibitors (DRB, FP, and IsoG), two splicing inhibitors (MY and SSA), and two exosomal siRNAs (RRP6 and RRP40) into groups reflecting their specific effects on these processes (Fig. 3a) . We compared this approach to traditional gene-expression analysis, in which samples are clustered on the basis of their effects on the mRNA expression levels of many genes. Clustering based on mRNA expression levels did not correctly classify inhibitors according to the specific stage of mRNA synthesis they affect (Fig. 3b) . Instead, mRNA expression was more likely to cluster samples by experimental batch, laboratory, or other criteria. Thus, simple ratiometric analysis of metagene profiles can be more effective than traditional gene-expression analysis for classifying compounds based on their influences on specific stages of gene expression.
IsoG does not function analogously to CDK9 inhibition
Given that IsoG appears to have a defect in transcription elongation, we asked whether it might function by inhibiting CDK9, similar to other transcriptional elongation inhibitors 1 . The CDK9 inhibitors s iR R P 4 0 ( R 2 E 1 ) DRB and FP prevent phosphorylation of the CTD of RNA polymerase II (Pol II), specifically at the Ser2 residue [8] [9] [10] . We found that IsoG also reduces the levels of pSer2 Pol II ( Fig. 4a; Supplementary  Fig. 3b ). The reduction in pSer2 Pol II by IsoG is dose responsive and reversible, as is with DRB or FP treatment (Supplementary Fig. 3c) . Moreover, the pSer2 reduction occurs without substantial alteration in the levels of pSer5 Pol II ( Fig. 4a; Supplementary Fig. 3b) , consistent with the idea that the transcriptional disruption caused by IsoG occurs after transcription initiation. We therefore tested the ability of IsoG to inhibit CDK9 itself. We found that IsoG has no effect on CDK9 activity as assessed using an in vitro kinase assay (Fig. 4b) . In control experiments, FP and DRB have the expected inhibitory effect on CDK9 activity (Fig. 4b) . These results, together with the distinct shape of the promoter-proximal RNA signal in IsoG-treated cells ( Fig. 2c; Supplementary Fig. 1b) , raise the possibility that IsoG inhibits promoter-proximal transcription elongation via a different mechanism than CDK9 inhibitors.
CDK9 inhibitors inhibit elongation most dramatically within the first several dozen nucleotides downstream of TSSs. To determine where elongation is inhibited in IsoG-treated cells, we used native elongating transcript sequencing (NET-seq), which maps Pol II with single nucleotide resolution 36 . The NET-seq read density at a genomic position is proportional to its Pol II occupancy. Upon IsoG treatment, NET-seq reveals a dramatic increase in promoterproximal relative to gene-body occupancy of RNA polymerase (Fig. 4c) . Because we did not use spike-in standards with NET-seq, these data do not indicate whether there is an absolute, as opposed to a relative, increase in promoter-proximal RNA polymerase. Nonetheless, they strongly support the IsoG-mediated promoterproximal elongation defect suggested by strand-specific total RNAseq ( Fig. 2; Supplementary Fig. 1) . Additionally, NET-seq revealed that IsoG, but not FP, treatment leads to an apparent transcription termination defect (Supplementary Fig. 4 ; compare to IsoG vs. DRB in Fig. 2c) , further confirming that strand-specific total RNA-seq can detect defects in specific transcriptional processes. Finally, the high resolution of NET-seq reveals that the promoter-proximal polymerase accumulation seen with IsoG treatment occurs in an extended, multi-kilobase region downstream of TSSs (Fig. 4c) . This extended region accumulation is in contrast to the more tightly promoter-proximal accumulation observed with NETseq upon FP treatment (Fig. 4d) 
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. The distinct promoter-proximal signatures of IsoG and FP further support the hypothesis that IsoG may inhibit a previously uncharacterized regulatory step in transcription elongation, specifically one that occurs subsequent to the CDK9-dependent RNA polymerase release from pausing.
Three distinct effects on elongation by IsoG, DRb/FP, CPT
Having used strand-specific total RNA-seq to identify specific premRNA synthesis defects caused by IsoG, we sought to further test the ability of RNA-seq to disentangle complex effects on pre-mRNA synthesis by testing a second small molecule, the topoisomerase I (Topo I) inhibitor camptothecin (CPT). Like IsoG, CPT has complex effects on pre-mRNA synthesis 37 . It has been reported to stimulate initiation of transcription 38 but also to inhibit transcription elongation 38 and slow transcription 39, 40 . Upon treatment with 1.0 μM CPT for 18 h, we observe decreasing pre-mRNA expression from 5′ to 3′ along the lengths of genes over tens to hundreds of kilobases (Fig. 5a,b) . This profile is consistent with inhibition of gene-body elongation that is independent of the polymerase's distance to its TSS, and it would be expected based on CPT-mediated introduction of covalent Topo I-DNA complexes at random locations throughout transcribed regions. To quantify this elongation defect, we created a 'density change across long gene bodies metric' , consisting of the ratio of pre-mRNA transcripts at 100-150 kb from the TSS compared to 200-250 kb from the TSS (Fig. 5c) . No other compounds that we tested had a gene-body elongation defect, with the notable exception of the splicing inhibitor SSA (Fig. 5c) . We speculate that splicing inhibition may affect gene-body elongation in a general but subtle manner that is detectable only when examining long genes. We also asked whether CPT affected other aspects of pre-mRNA synthesis. We observed a modest increase in sense and antisense promoter-proximal transcripts upon CPT treatment (Fig. 5b,  inset) , possibly due to previously reported increases in transcription initiation or defects in promoter-proximal elongation. Using our metrics, we did not detect defects in splicing or in transcription termination upon CPT treatment (Fig. 5d) , as was reported for higher CPT concentrations 41 . The ability of strand-specific total RNA-seq not only to detect an elongation defect caused by CPT but also to clearly distinguish it from the elongation defects caused by IsoG and DRB further establishes total RNA-seq as having the ability to identify and isolate pharmacological effects on distinct stages of mRNA synthesis.
DISCUSSIoN
We show here that metagene analysis of strand-specific total RNAseq can be used to detect and distinguish pharmacological effects on transcription elongation, splicing, exosome function, and transcription termination. In the case of transcription elongation, our method can distinguish at least three major locations at which smallmolecule-mediated transcription elongation inhibition occurs: at the promoter (CDK9 inhibition), near the promoter (IsoG), and across the remainder of gene bodies (topoisomerase I inhibition). In a demonstration of the utility of our approach, we have recast the natural product IsoG, previously identified as an inhibitor of splicing 19 , as a blocker of transcription elongation. In light of IsoG's effect on transcription elongation, the effects of IsoG on splicing in vivo become difficult to assess. Transcription elongation in IsoG-treated cells is so profoundly altered that traditional metrics of splicing, including the ratios of introns to exons, are not easily interpretable. While IsoG does appear to inhibit splicing in vitro 19 and in vivo 20 after controlling for its effects on transcription, the specific in vivo effects on splicing are relatively small (~2-fold) 20 compared to those on transcription elongation (~10-fold; Fig. 2d ). More generally, our results suggest that the current paucity of splicing inhibitors may be in part due to the difficulty of designing in vivo screening assays 42, 43 that exclude the kinds of effects on transcription seen with IsoG.
Our application of total-RNA-seq-based metrics for small-molecule characterization opens the door to identification of many more compounds that block specific stages of pre-mRNA synthesis. At the same time, it will be important to follow up strand-specific total RNA-seq analysis with more directed assays, for several reasons. First, while powerfully simplifying, our metrics are not unambiguously interpretable on a stand-alone basis. In one example, the apparently stronger effect of IsoG compared to DRB and FP on promoter-proximal elongation (Fig. 2d) could be caused by a bias in our RNAseq method disfavoring detection of the short (<60 bp) transcripts that are produced upon FP or DRB treatment 32 . Second, our metrics rely on built-in assumptions that may need to be altered to interpret the effects of new compounds. IsoG's elevation of promoterproximal transcript abundance is observed <5 kb from the TSS, so 9-10 kb here served as a useful gene-body reference point for the TSS/gene-body ratio metric (Supplementary Fig. 2a-e) . For other compounds, or potentially even alternative doses of the same compound, it may be necessary to choose a different gene-body reference point. It should be possible to develop more refined and more general metrics as RNA-seq profiles for additional compounds are analyzed. Finally, our metrics would benefit from more extensive validation. For example, it will be important to confirm that the PAS-downstream/PAS metric is able to capture known termination defects caused by changes in the rates of polymerization or Xrn2-mediated exonuclease activity 44, 45 . Crucial to strand-specific total RNA-seq-based screening efforts will be two practical elements that make our approach highly scalable. First is the availability of multiplex RNA-seq library preparation methods 46 , with sample pooling at an early stage to reduce the cost of reagents and labor. This kind of highly scalable multiplexing has not yet been achieved for related methods such as NET-seq 36 , GRO-seq 47 , or metabolic labeling 48, 49 , perhaps in part because each of these methods is substantially more complex. Consequently, these other methods have not yet been applied to simultaneously assess the effects of many small molecules on multiple steps of RNA processing. Equally importantly, we focus our method here on metagene-based metrics, which enables us to achieve high sensitivity with just one million sequencing reads (Supplementary Fig. 5 ) and makes it possible to analyze hundreds of libraries in a single sequencing run. We anticipate that this strategy could rapidly enable the identification of hundreds of small molecules that influence gene expression and could facilitate secondary screening to classify compounds based on their effects on specific stages of gene expression. 
references oNLINE mETHoDS
Cell culture and pharmacological treatments. HeLa cells were obtained from the ATCC and were not authenticated for this study. HeLa cells were maintained in DMEM supplemented with 10% FBS, 1% penicillin-streptomycin, 1% nonessential amino acids. Cells were plated to about 70% confluence the day before any drug treatments on 10-cm plates. Cells were treated with inhibitors at the following doses unless otherwise noted: 30 uM isoginketin (IsoG, Millipore), 100 μM 5,6-dichlorobenzimidazole 1-β-D-ribofuranoside (DRB, Sigma), 300 nM flavopiridol (FP, Sigma), or 80 nM meayamycin (gift from K. Koide) for 6 or 18 h as indicated. For time-course data, cells were treated at different times, such that all cells were lysed at the same time. For reversibility washout experiments, cells were treated with drug for 3 h then washed two times with warm PBS before adding fresh warmed media.
RNA extraction. At the time of harvest for RNA, cells were washed 1× with PBS and then lysed with RLT buffer (Qiagen). Samples were immediately processed with QIAshredder and RNeasy kits (Qiagen) and frozen until further use. 9 μg of RNA was DNase treated and cleaned up with RNeasy MinElute kit (Qiagen). RNA quality was assessed by Bioanalyzer (Agilent) and all correct samples had RNA integrity numbers (RINs) of 9.0 or higher.
RNA-seq experiment summary. We performed four RNA-seq experiments and one NET-seq experiment, submitted to GEO (accession GSE86857). The first RNA-seq experiment tested IsoG and DRB in HeLa cells, and compared strand-specific total RNA to strand-specific poly(A) + RNA. The second compared IsoG, DRB, and FP treatments in HeLa cells. The third tested meayamycin (MY) in HeLa cells. Each of the first three experiments used the dUTP (2´-deoxyuridine, 5-triphosphate) method. We also used previously published NET-seq data for DMSO vs. FP (GSM1505442 and GSM1505443) 36 .
Illumina library construction and sequencing. dUTP method. RNA-seq libraries were constructed using the strand-specific dUTP method 50 , with minor modifications. Input amounts of RNA varied between 3-5 μg with the proportional amount of ERCC spike in RNA (Ambion). For each batch experiment total amounts of input RNA were consistent across the samples. For poly(A) + RNA, DNAse-treated RNA was enriched for poly(A) + RNA using Dynabeads mRNA purification (Ambion). For strand-specific total RNA libraries, DNAsetreated RNA was depleted of rRNA using Ribo-Zero (Epicentre), then samples were cleaned up using the RiboMinus concentration module (Invitrogen) and fragmented at 90 °C for 3 min using NEB fragmentation buffer. First-strand synthesis was followed by cleanup with RNAClean XP SPRI beads (Agencourt). Second-strand synthesis incorporated dUTP, which was followed by sample clean up with MinElute PCR purification kit (Qiagen). Fragment ends were repaired, adenylated, and then ligated to True-seq barcoded adaptors and cleaned up with AMPure XP SPRI beads (Agencourt). The libraries were then amplified by PCR for 9-12 cycles and cleaned up with AMPure XP SPRI beads. Illumina sequencing (1× 50 bp read length) was performed on a HiSeq 2000.
NET-seq. HeLa S3 cells (ATCC, CCL-2.2) were maintained in DMEM media containing 10% FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin to 75% confluency. For drug treatment, media was replaced with DMEM containing either 30 μM isoginkgetin (IsoG, Millipore) or 0.6% DMSO for 6 h. The NETseq protocol was performed as described in ref. 51 with modifications described below. In brief, chromatin-associated RNA is enriched by cellular fractionation 52 . A DNA linker is ligated specifically to the 3′ hydroxyl group on nascent RNA, representing the active site of Pol II 53 . The ligation step was performed overnight at 16 °C using a DNA linker with a random hexamer sequence to improve ligation efficiency and computationally remove library preparation biases. All RNA purification steps were performed on a column (RNA Clean & Concentrator-5 kit, Zymo Research). DNA sequencing libraries were prepared from ligated nascent transcripts and sequenced on an Illumina NextSeq 500 instrument with a read length of 75 base pairs. Sequencing reads were processed and aligned exactly as described in ref. 36 using STAR (v2.4.2a) 54 . Aligned reads were then processed and plotted exactly as with total RNA-seq (see below). For our NET-seq experiment, there were no spike-ins, so we normalized each sample to the maximum (sense) bin in each metaplot.
Protein extraction and western blotting. At the time of protein harvest, cells were washed 2× with cold PBS then lysed with protein lysis buffer: PBS, 1 mM sodium orthovanadate, 10 mM sodium fluoride, 10 mM sodium pyrophosphate, 50 mM B-glycerol phosphate, and EDTA-free cOmplete Protease Inhibitor Cocktail (Roche). Lysates were immediately frozen in liquid nitrogen until being lysed by two freeze-thaw cycles and vortexed. Equal amounts of protein per sample were separated by SDS-PAGE and transferred to a nitrocellulose membrane by iBlot electroblotting (Life Technologies). After the membranes had been incubated with primary (1:1,000 dilutions) and secondary antibodies (1:2,000 dilutions), chemiluminescent detection was performed with the Western-Lighting ELC (PerkinElmer) and developed using CL-XPosure Film (Thermo). Antibodies used for western blogging were: Actin (A2066; Sigma), RNA pol II CTD phospho Ser2 (3E10; Active Motif), and the RNA pol II CTD phospho Ser5 (3E8; Active Motif).
RNA-seq analysis, normalization, and metaplot construction. The total RNAseq analysis framework and pipeline used here is distinct from our previously published ones 20 . We trimmed reads with fastx v0.0.13, aligned them to hg37 using STAR v2.2.1, and mapped to RefSeq exons and introns using bedtools v2.25.0. We summed ERCC alignment counts using FeatureCounts v1.5.3. To make TSS and PAS metaplots that show average expression across many genes aligned at their TSS or PAS, we used the metaseq v0.5.6 module in Python to export text files that we analyzed in R. For these metaplots, we excluded any reads aligning to RefSeq annotated exons, as our interest was in pre-mRNA and other nascent transcripts. TSS-and PAS-centered metaplots were made by summing all nonexonic reads of genes longer than the maximum x-axis value in the metaplot (typically 10 kb). To create metaplots showing absolute levels of expression, we normalized to the total number of aligned ERCC spike-in control reads. For each of these ERCC spike-in-normalized metaplots, we subtracted genomic background transcription by subtracting the mean sense read density in the [−10 kb to −5 kb] region (upstream of the TSS). We used this background subtraction because some compounds (i.e., IsoG) appear to increase genic and extragenic background transcription (Supplementary Fig. 1e ). For our CPT experiment, we did not include ERCC spike-ins, so we instead normalized to the number of mRNA (exon)-aligned reads at least 10 kb from TSSs. The latter criterion filters out potentially confounding effects of changes in promoter-proximal transcript abundance between samples. To create metaplots to compare promoter-proximal versus pre-mRNA (promoter distal) expression, we normalized to the maximum average expression without upstream genomic background subtraction. In all metaplots, we removed genes above the 99.9th percentile of expression in the region plotted, as a method of spike filtering. The intron/exon metric assesses splicing by comparing the overall ratio of intronic to exonic read densities, based on intronic and exonic read densities [9-10 kb] relative to annotated TSSs. The choice of [9-10 kb] for the splicing defect metric minimizes the contribution of promoter-proximal transcripts that would dominate this metric if we included more promoter-proximal regions. The density change across long gene bodies metric assesses the ratio of reads [100-150 kb] to [200-250 kb] relative to the TSS for genes that are at least 250 kb in length. This metric also uses an additional spike filter. Read densities were calculated for bins of 100 bp. If any bin differed from its neighboring bins by over ten-fold in density (ignoring bins with zero reads) the value of the bin was replaced with the average of its neighbors. This filter modifies a small fraction of the total bins; the elevated counts are likely due to features that were missed in the RefSeq genome annotation. All metrics use background-subtracted [−10 to −5 kb] average read densities, with the exception of the long gene-body elongation metric. In the case of the density change across long gene bodies metric, the small number of long (>250 kb) genes leads to significant noise in the upstream background, so we did not perform this correction. To allow for comparison between experiments, all small-molecule or knockdown metrics are normalized to their matching control samples.
Data analysis and statistics. RNA-seq of drug treatments were typically performed in duplicate or triplicate. This is not enough measurement to directly test whether each treatment has the same variance. Instead we confirmed that across all measurements the RNA-seq technique replicates follow a normal distribution and used this confirmation of normality as a prior when assessing the significance of all other measurements. In conformance with journal policy, given the number of measurements, we display the data points instead of mean and variance. Because we did not have a predetermined hypothesis, we Bonferroni corrected our statistical tests by the number of metrics we examined. Clustering was performed using MATLAB. For clustering, metrics and mRNA expression values were ratioed to within-experiment controls before clustering, and the TSS/gene-body ratio and absolute gene-body metrics were inverted to avoid introduction of noise due to division by small numbers.
Code availability. Custom MATLAB code was written to calculate the metrics. Code available upon request.
Data availability. Four RNA-seq experiments and one NET-seq experiment were submitted to GEO (accession code GSE86857). Previously published data sets used in this study can also be found on GEO. NET-seq data on HeLa S3 cells treated with FP is GSM1505443 (ref. 36 ). Strand-specific total RNA-seq data from exosome knockdown and SSA-treated HeLa cells with matched IsoG treatment is from GSE73776 (ref. 21 ).
